# Repligen Corporation  Share Price Target ‘$187.23’, now -7.2% Downside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-share-price-target-187.23-now-7.2-downside-potential/4121141910
- Published: 2024-02-09T14:40:20+00:00
- Author: Charlotte Edwards

**Repligen Corporation** with ticker code (RGEN) now have 12 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The target price High/Low 
ranges between $211.00 and $148.00 suggesting an average analyst share price target
price of $187.23. (at the time of writing). Given that the stocks previous close
was at $201.75 this would imply there is a potential downside of -7.2%. There is
a 50 day moving average of $177.93 and the 200 day moving average is $162.40. The
market capitalization for the company is 11.39B. The stock price is currently at:
$203.99 USD

 The potential market cap would be $10,569,488,160 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 100, revenue per share of $12.04 and a 2.08% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: